Skip to main content

Table 1 Relationship between syndecan-1 immunoreactivity and clinicopathological characteristics

From: Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: An immunohistochemical study of clinically annotated tumors

  Syndecan-1 staining (percentage of tumors in brackets)
  0 1+ 2+ 3+  
  n = 38 (29%) n = 27 (21%) n = 49 (37%) n = 17 (13%) p
Variable      
Age      0.651
   <65 yrs 16 (42.1) 12 (44.4) 17 (34.7) 6 (35.3)  
   ≥ 65 yrs 22 (57.9) 15 (55.6) 32 (65.3) 11 (64.7)  
Gender      0.042*
   Male 24 (63.2) 22 (81.5) 23 (46.9) 10 (58.8)  
   Female 14 (36.8) 5 (18.5) 26 (53.1) 7 (41.2)  
Stage      0.045*
   I/II 14 (36.8) 13 (48.1) 33 (67.3) 9 (52.9)  
   III/IV 24 (63.2) 14 (51.9) 16 (32.7) 8 (47.1)  
Lymph node metastasis      0.017*
   negative 16 (42.1) 14 (51.9) 36 (73.5) 12 (70.6)  
   positive 22 (57.9) 13 (48.1) 13 (26.5) 5 (29.4)  
Location      0.380
   Proximal 13 (34.2) 9 (33.3) 13 (26.5) 2 (11.8)  
   Distal 25 (65.8) 18 (66.7) 36 (73.5) 15 (88.2)